What smart money is saying about Bruker Corp
1 fund in our archive has pitched Bruker Corp — most recently Artisan U.S. Small-Cap Growth Strategy in December 2025.
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Get an email when a fund buys, sells or pitches it
Position history
Between Q3 2025 and Q3 2026, 7 fund letters reported a position in Bruker Corp — 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2 | 0 |
| Q2 2026 | 2 | 0 | 0 | 0 |
| Q1 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q3 2025 | 1 | 0 | 0 | 0 |
Fund activity · 7 positions · 2 moves
- September 2026
“In healthcare the fund exited medical device company Bruker, which was trimmed into strength last quarter, and trimmed biotechnology platform Humacyte whilst adding to Brookdale as mentioned above.”
Bruker Corp - September 2026
“● Exited: Bruker Corporation (BRKR) – Sold the small position after a rally.”
Bruker Corp - July 2026
“10 Largest Holdings % OF TOTAL ASSETS Cumulative Performance Discrete Performance The Fund aims to provide capital growth over the long term (periods of 5 years or more), by investing in companies”
Bruker Corp - June 2026
“The fund outperformed its benchmark over the quarter. This was the result of positive stock selection, with holdings in the information technology and healthcare sectors performing particularly well. Some of the best performers were stocks benefiting from investors’ increasingly positive view on the semiconductor cycle and AI-related demand. Holdings in the Intel and Micron Technology were among the fund's strongest contributors. The holding in scientific equipment manufacturer Bruker performed well.”
Bruker Corp - June 2026
“ Bruker Corp (BRKR) shares began the quarter at ~15x next twelve months (NTM) earnings per share (EPS), a valuation it has not touched in over a decade.”
Bruker Corp - March 2026
“NCR Voyix Corporation (VYX) provided 2026 guidance that was materially below street estimates. The disparity is partially a result of the company's transition to outsourced manufacturing of its hardware but also reflects small and medium-sized business headwinds. In January 2026, the company launched its next generation platform that was well received at the National Retail Federation conference. Early wins include a significant 5-year exclusive agreement with Pilot Travel Centers. Shares of Bruker Corporation (BRKR) fell sharply during the quarter, following disappointing guidance for 2026 that was heavily weighted towards the back half of the year. Continued pressure on the NIH budget has also weighed on the company.”
Bruker Corp - HoldsVela Small Cap FundSeptember 2025
“In the Health Care sector, Life Science Instruments company, Bruker Corporation (BRKR), reported disappointing second quarter results, driven by continued weakness in the US academic market as well as in the biopharma and industrial end markets. Also during the third quarter, BRKR issued dilutive convertible preferred securities to pay down debt and improve the balance sheet. The US academic market should stabilize and rebound once there is some clarity around the FY 2026 NIH budget. BRKR’s competitive position remains strong.”
Bruker Corp
Also mentioned · 1
These funds discuss Bruker Corp — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“The trust outperformed its benchmark over the quarter. This was the result of positive stock selection, with holdings in the information technology and healthcare sectors performing particularly well. Some of the best performers were stocks benefiting from investors’ increasingly positive view on the semiconductor cycle and AI-related demand. Holdings in the Intel and Micron Technology were among the fund's strongest contributors. The holding in scientific equipment manufacturer Bruker performed well.”
Bruker Corp
Fund coverage · 1 thesis
- Artisan U.S. Small-Cap Growth StrategyDecember 2025
Bruker Corp is a leading scientific instruments provider with profit-cycle tailwinds from innovation and acquisitions as funding headwinds ease.
Read the full thesis
Read every full thesis on Bruker Corp
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→